Abstract: ABSTRACT The presently described compounds relate to the treatment of diabetes and/or 5 hyperglycemia. More particularly, the described compounds relate to acylated insulin compounds that lower blood glucose, pharmaceutical compositions containing such compounds, therapeutic uses of such compounds, and an intermediate compound used to make the acylated insulin compounds.
Description:AS FILED PDF DOCUMENT , Claims:AS FILED PDF DOCUMENT
| # | Name | Date |
|---|---|---|
| 1 | 202418025025-STATEMENT OF UNDERTAKING (FORM 3) [28-03-2024(online)].pdf | 2024-03-28 |
| 2 | 202418025025-Sequence Listing in txt [28-03-2024(online)].txt | 2024-03-28 |
| 3 | 202418025025-Sequence Listing in PDF [28-03-2024(online)].pdf | 2024-03-28 |
| 4 | 202418025025-REQUEST FOR EXAMINATION (FORM-18) [28-03-2024(online)].pdf | 2024-03-28 |
| 5 | 202418025025-Proof of Right [28-03-2024(online)].pdf | 2024-03-28 |
| 6 | 202418025025-POWER OF AUTHORITY [28-03-2024(online)].pdf | 2024-03-28 |
| 7 | 202418025025-FORM-26 [28-03-2024(online)].pdf | 2024-03-28 |
| 8 | 202418025025-FORM 18 [28-03-2024(online)].pdf | 2024-03-28 |
| 9 | 202418025025-FORM 1 [28-03-2024(online)].pdf | 2024-03-28 |
| 10 | 202418025025-DECLARATION OF INVENTORSHIP (FORM 5) [28-03-2024(online)].pdf | 2024-03-28 |
| 11 | 202418025025-COMPLETE SPECIFICATION [28-03-2024(online)].pdf | 2024-03-28 |
| 12 | 202418025025-FORM 3 [29-08-2024(online)].pdf | 2024-08-29 |